利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.023 秒)

    Activated vapor treatment for neutralizing warfare agents
    1.
    发明申请
    Activated vapor treatment for neutralizing warfare agents 有权
    用于中和战剂的活性蒸气处理

    公开(公告)号：US20060205991A1

    公开(公告)日：2006-09-14

    申请号：US10554223

    申请日：2004-04-23

    申请人： Iain McVey ,  Lewis Schwartz ,  Michael Centanni ,  George Wagner

    发明人： Iain McVey ,  Lewis Schwartz ,  Michael Centanni ,  George Wagner

    IPC分类号： A62D3/00

    CPC分类号： A62D3/38 ,  A61L2/20 ,  A61L2/208 ,  A61L2202/23 ,  A62D2101/02

    摘要： Hydrogen peroxide is vaporized (20) and mixed (30) with ammonia gas in a ratio between 1:1 and 1:0.0001. The peroxide and ammonia vapor mixture are conveyed to a treatment area (10) to neutralize V-type, H-type, or G-type chemical agents, pathogens, biotoxins, spores, prions, and the lip-, e. The ammonia provides the primary deactivating agent for G-type agents with the peroxide acting as an accelerator. The peroxide acts as the primary agent for deactivating V-type and H-type agents, pathogens, biotoxins, spores, and prions. The ammonia acts as an accelerator in at least some of these peroxide deactivation reactions.

    摘要翻译： 过氧化氢蒸发（20）并与氨气比例为1:1至1:0.1之间混合（30）。 将过氧化物和氨蒸汽混合物输送到处理区域（10）以中和V型，H型或G型化学试剂，病原体，生物毒素，孢子，朊病毒和唇部， 氨提供G型试剂的初级钝化剂，其中过氧化物作为促进剂。 过氧化物作为使V型和H型药物，病原体，生物毒素，孢子和朊病毒失活的主要药剂。 在这些过氧化物失活反应中的至少一些中，氨充当促进剂。

    Activated oxidizing vapor treatment system and method
    2.
    发明申请
    Activated oxidizing vapor treatment system and method 审中-公开
    活性氧化蒸汽处理系统及方法

    公开(公告)号：US20060252974A1

    公开(公告)日：2006-11-09

    申请号：US11401649

    申请日：2006-04-11

    申请人： Iain McVey ,  Lewis Schwartz ,  Michael Centanni ,  Gerald McDonnell

    发明人： Iain McVey ,  Lewis Schwartz ,  Michael Centanni ,  Gerald McDonnell

    IPC分类号： A62D3/00

    CPC分类号： A62D3/38 ,  A61L2/202 ,  A61L2/208 ,  A62D2101/02

    摘要： An oxidizing liquid (20), such as hydrogen peroxide, is vaporized (18) and the vapor is used to deactivate nerve gas, blistering gas, or other biologically active substances such as pathogens, biotoxins, and prions. A second chemical compound (42) in vapor, mist, or fog form is used in conjunction with the oxidizing vapor. In one embodiment, the second chemical preconditions the biologically active substances to be deactivated more efficiently by the oxidizing vapor. In another embodiment, the second chemical boosts the reactivity of the oxidizing vapor. In another embodiment, the other chemical reacts with the oxidizing vapor to form an intermediate compound that deactivates at least some of the biologically active substances.

    摘要翻译： 蒸发氧化液体（20）如过氧化氢（18），蒸汽用于使神经气体，起泡气体或其他生物活性物质如病原体，生物毒素和朊病毒失活。 蒸汽，雾或雾形式的第二化合物（42）与氧化蒸气结合使用。 在一个实施方案中，第二化学品通过氧化蒸气更有效地预先使待生物活性物质失活。 在另一个实施方案中，第二化学物质增强氧化蒸气的反应性。 在另一个实施方案中，其它化学物质与氧化蒸气反应形成中和化合物，其使至少一些生物活性物质失活。

    Integrated control and distribution system for the decontamination of large volume convoluted configuration spaces
    3.
    发明申请
    Integrated control and distribution system for the decontamination of large volume convoluted configuration spaces 有权
    集成控制和分配系统，用于大容量卷积配置空间的去污

    公开(公告)号：US20070140893A1

    公开(公告)日：2007-06-21

    申请号：US10593662

    申请日：2005-03-23

    申请人： Iain McVey ,  Paul Wiget ,  Michael Centannia ,  Lewis Schwartz

    发明人： Iain McVey ,  Paul Wiget ,  Michael Centannia ,  Lewis Schwartz

    IPC分类号： A61L2/20

    CPC分类号： A61L2/208 ,  A61L2/202 ,  A61L2/24 ,  A61L9/015

    摘要： A large convoluted space, such as a multi-story concourse of an airport is isolated and a chemical or biological agent in the concourse is deactivated. A plurality of deactivation gas sources (100) introduce a deactivation gas at multiple points along the concourse. Fans (66, 106) circulate the deactivation gas, sensors (110) sense concentrations of the deactivation gas at numerous points around the concourse and exhaust fans (66) exhaust air, spent deactivation gas, and some deactivation gas. A control processor (84) controls the generators, the circulation fans, and the exhaust fans in accordance with the gas concentrations sensed by the sensors to increase and decrease deactivation gas concentration in selected subregions of the concourse by increasing or decreasing generation, increasing or decreasing exhausting, or altering flow patterns among subregions.

    摘要翻译： 大型复杂的空间，例如机场的多层大厅是孤立的，大厅内的化学或生物制剂被停用。 多个失活气体源（100）沿着大厅的多个点引入失活气体。 风扇（66,106）使失活气体循环，传感器（110）在大气和排气风扇（66）周围的许多点处感测失活气体的浓度排出空气，废失活气体和一些失活气体。 控制处理器（84）根据传感器感测到的气体浓度来控制发电机，循环风扇和排风扇，以通过增加或减少发电量，增加或减少来增加和减少选定的大厅区域中的失活气体浓度 耗尽或改变次区域之间的流动模式。

    Delivery of highly lipophilic agents via medical devices
    5.
    发明申请
    Delivery of highly lipophilic agents via medical devices 审中-公开
    通过医疗器械递送高度亲脂性的药剂

    公开(公告)号：US20060240070A1

    公开(公告)日：2006-10-26

    申请号：US11386587

    申请日：2006-03-22

    申请人： Keith Cromack ,  John Toner ,  Sandra Burke ,  Richard Krasula ,  Lewis Schwartz

    发明人： Keith Cromack ,  John Toner ,  Sandra Burke ,  Richard Krasula ,  Lewis Schwartz

    IPC分类号： A61F2/20 ,  A61K38/17 ,  A61K48/00

    CPC分类号： A61L31/16 ,  A61L27/34 ,  A61L27/54 ,  A61L29/085 ,  A61L29/16 ,  A61L31/10 ,  A61L2300/00 ,  A61L2300/416 ,  A61L2300/45 ,  A61L2300/604

    摘要： An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen.

    摘要翻译： 一种用于递送与医疗装置相关联的亲脂剂的装置和系统，包括：医疗装置，能够穿透体腔的第一亲脂性试剂，其中第一亲脂性试剂的转移系数为统计学上显着的 至少约5,000，其中所述第一亲脂性试剂与所述医疗装置相关联，其中所述第一亲脂性试剂/医疗装置放置在所述体腔附近，并且其中治疗有效量的所述第一亲脂性试剂被递送至 课程。 此外，本发明涉及一种用于提高受试者通畅的方法，包括将医疗装置放置在体腔中，用于治疗和/或预防相邻疾病或维持体腔通畅。